Developing a sustainable engineered microbiota for treating male pattern baldness

Prof. Boaz Mizrahi | Biotechnology and Food Engineering
Prof. Roee Amit | Biotechnology and Food Engineering


Pharmaceuticals and Biotechnology

The Technology

Male pattern baldness affects over a quarter of the male population above age 35 worldwide. Over production of DHT from Testosterone in man and its accumulation in the hair follicles, is strongly correlated with hair loss. There is no known permanent treatment, aside for surgical replacement of hair. Current FDA approved non-surgical treatments only partially works and generated unwanted side effects. The technology provides atopic treatment based on genetically engineered B. Subtilis bacteria found on skin including the human scalp, which were altered to secrete an enzyme called 3α-HSD which has been shown to break down DHT very effectively. The bacteria can generate a slow and constant release of the enzyme and would be embedded inside the patient’s skin microbiome (microorganism population) using a polymeric formulation (Pluronic), leading to stable embedding of the engineered strain. The formulation will be applied once to the skin and the bacteria will become embedded within the natural skin microbiome, resulting in a sustainable topical treatment that will preclude the need for reapplication and essentially eliminate all potential side-effects that are associated with a repetitive application of treatment


  • Efficient and should reduce side effects
  • Treatment active for several days
  • Specific to applied skin area
  • The platform technology will be able to support a variety of other applications

 Applications and Opportunities

  • Efficient external use skin treatment for male pattern baldness, and other skin conditions
arrow Business Development Contacts
Dr. Gal Gur
Director of Business Development, Life Sciences